PositiveID Corporation announced that it has acquired intellectual property rights and assets of Easy Check Medical Diagnostics, to expand its portfolio of non-invasive glucose-level testing products and diabetes management tools under development.
Easy Check has two primary products under development: the Easy Check breath glucose detection system and the iGlucose wireless communication device. PositiveID is also developing an in vivo glucose-sensing RFID microchip to detect glucose levels in the human body.
PositiveID’s glucose-sensing RFID microchip is in Phase II of development and is expected to be completed by mid-2010. The system has already successfully demonstrated application of the glucose-sensing system for the detection of glucose levels.
The Easy Check breath test measures acetone levels in a patient’s exhaled breath to determine glucose levels. This eliminates the need for a patient to prick his or her finger multiple times per day to get a blood sugar reading.
Easy Check’s iGlucose system uses wireless SMS messaging to automatically communicate a diabetic’s glucose readings to the iGlucose online database, providing real-time data to improve diabetes management and helps ensure patient compliance, data accuracy and insurance reimbursement.